ChipDX identifies gene expression signature in early-stage breast tumors
ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.
Linear Mode
